BETA-地中海型貧血檢測市場 - 全球產業規模、佔有率、趨勢、機會、預測：按產品、技術、類型、最終用戶、地區和競爭對手分類，2021-2031年

全球BETA-地中海貧血檢測市場預計將從2025年的6.1495億美元成長到2031年的10.5309億美元，複合年成長率達到9.38%。

該市場依賴血液常規檢查、血紅蛋白電泳和分子遺傳分析等診斷檢測方法來檢測由HBB基因突變引起的血紅蛋白缺乏症。成長的主要促進因素是全球遺傳性血液疾病發生率的上升，以及高風險地區強制性婚前和產前篩檢政策的實施。此外，旨在早期疾病管理以減輕終身輸血帶來的經濟負擔的公共衛生宣傳活動，也持續加速了這些診斷解決方案的普及應用。

儘管有這些正面跡象，但在醫療資源匱乏、醫療資金不足的環境中，全面診斷的普及仍面臨嚴峻挑戰。基因檢測的高昂自付費用阻礙了新興經濟體的普及，也成為疾病控制的一大障礙。國際地中海貧血聯合會預測，到2024年，超過80%的中高發病率國家將缺乏國家層面協調和支持的預防項目，凸顯了診斷需求與現有基礎設施之間存在的巨大差距。

市場促進因素

政府主導的新生兒和產前篩檢計畫的擴展是全球BETA-地中海貧血檢測市場的主要驅動力，尤其是在亞洲和地中海等高發生地區。各國政府正加速推動大規模篩檢項目，以便及早發現帶因者，並減輕治療輸血依賴型患者所帶來的長期經濟負擔。這項監管轉變正在將以往分散的檢測模式轉變為一項系統的公共衛生優先事項，從而顯著增加年度診斷檢測量。例如，印度衛生和家庭福利部報告稱，截至2025年3月，全國篩檢計畫已成功篩檢了1,587,903名地中海篩檢患者，顯示政府主導的干涉規模龐大。

同時，分子診斷技術的進步和基因療法的商業化正在重塑市場格局，對精準的基因分型至關重要。基因編輯療法的核准和應用需要嚴格的分子檢測來驗證患者合格並追蹤治療效果，從而推動了對高度複雜基因檢測的需求。根據Vertex Pharmaceuticals於2025年8月發布的2025年第二季財報，自Casgevy基因療法問世以來，全球已有約115名患者開始進行細胞採集，這直接刺激了伴隨診斷通訊協定市場的發展。然而，差距依然存在。正如國際地中海貧血聯合會在2025年3月指出的那樣，中低收入國家超過75%的患者面臨血液短缺，這凸顯了建立便捷的診斷基礎設施以提升傳統和先進治療水平的迫切需求。

市場挑戰

阻礙全球BETA-地中海貧血檢測市場擴張的主要障礙是資源匱乏地區經濟准入的嚴重不足，這源自於醫療資金不足和高昂的自付費用。在許多新興經濟體，基因檢測的高昂費用是進入該市場的主要障礙。當家庭被迫承擔全部醫療費用時，他們必須優先考慮維持生存所需的緊急治療，而非預防性診斷，這反過來又抑制了高發地區對篩檢檢測的需求。這種經濟限制縮小了診斷試劑生產商能夠有效參與的市場規模，因為進入醫療基礎設施不足以支持這些關鍵檢測的地區十分困難。

為了佐證這種經濟壓力，國際地中海貧血聯合會2024年的報告指出，在90%以上地中海貧血中高發國家，患者仍需要自費支付醫療費用。這種對個人資金的嚴重依賴與低檢測率直接相關，因為對於很大一部分高風險族群而言，由於無力支付後續治療費用，初次診斷本身就造成了經濟負擔。

市場趨勢

在分散式環境中，即時診斷（POC）設備的興起正在從根本上改變BETA-地中海貧血檢測的可及性，尤其是在缺乏集中式實驗室的地區。這一趨勢標誌著檢測方式從依賴複雜的高效液相層析（HPLC）系統轉向使用攜帶式電池驅動裝置，這些設備能夠在當地診所提供明確的診斷結果。這些設備能夠實現現場篩檢和診斷，解決了重大的物流難題，並大幅降低了因需要長途跋涉進行追蹤預約而導致的患者流失率。這種發展趨勢正在推動對行動解決方案的生產和分銷管道進行大量投資。例如，2025年9月，MedAccess宣布與Hemex Health建立策略合作夥伴關係，提供250萬美元的營運資金框架，以擴大該公司「Gazelle」診斷平台的覆蓋範圍。 Gazelle是首款能夠在資源匱乏的市場中定量檢測BETA-地中海貧血血紅蛋白變異體的攜帶式設備。

同時，次世代定序（NGS）技術的引入，為精準診斷建立了新的標準，用於檢測那些常被傳統方法忽略的罕見複雜突變。隨著臨床管理向個體化方向發展，實驗室正從傳統的電泳方法轉向高通量定序平台，以識別非缺失突變和影響疾病嚴重程度的修飾因子。這種技術變革對於預防嚴重出生缺陷至關重要，因為它可以在遺傳多樣性受限的人群中進行更精準的帶因者篩檢。為了驗證這種準確性的提升，華大基因於2025年5月在《遺傳學與基因組篩檢雜誌》（Journal of Genetics and Genomics）上發表的一項研究表明，對28,043名育齡婦女進行高通量定序，能夠準確識別罕見的血紅蛋白變異，其檢出率優於傳統的血液學篩檢方法。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球BETA-地中海貧血檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（套裝、耗材）
  • 透過技術手段（產前診斷、全血球計數、DNA檢測等）
  • 依類型（重地中海型貧血、中間型地中海型貧血）
  • 依最終使用者（醫院、專科診所、診斷中心等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美BETA-地中海貧血檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲BETA-地中海型貧血檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區BETA-地中海貧血檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲BETA-地中海貧血檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲BETA-地中海貧血檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球BETA-地中海貧血檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• MedGenome
• 3B BlackBio Biotech India Limited
• Bio-Rad Laboratories Inc.
• ViennaLab Diagnostics
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• BioMedomics Inc.
• Asper Biogene
• Tosoh Bioscience Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Beta Thalassemia Testing Market is projected to expand from USD 614.95 Million in 2025 to USD 1053.09 Million by 2031, achieving a CAGR of 9.38%. This market relies on diagnostic assays, including Complete Blood Count, hemoglobin electrophoresis, and molecular genetic analysis, to detect hemoglobin deficiencies resulting from HBB gene mutations. Growth is chiefly propelled by the rising global incidence of hereditary blood disorders alongside the implementation of mandatory premarital and prenatal screening policies in high-risk areas. Furthermore, public health campaigns aimed at early disease management to alleviate the financial strain of lifelong transfusion therapies continue to encourage the uptake of these diagnostic solutions.

Despite these positive indicators, the market confronts substantial hurdles regarding the availability of comprehensive diagnostics in resource-constrained environments lacking adequate healthcare funding. The significant out-of-pocket expenses required for genetic verification frequently discourage widespread utilization in emerging economies, establishing a formidable barrier to disease control. According to the Thalassaemia International Federation, in 2024, nationally coordinated and supported prevention programmes were nonexistent in over 80% of countries with medium to high disease prevalence, highlighting the severe gap between diagnostic necessities and the existing infrastructure.

Market Driver

The broadening of government-enforced newborn and prenatal screening initiatives serves as the principal engine driving the Global Beta Thalassemia Testing Market, especially within high-prevalence zones in Asia and the Mediterranean. Governments are increasingly establishing large-scale screening programs to detect carriers early and reduce the long-term financial burden associated with treating transfusion-dependent patients. This regulatory momentum is transforming a previously disjointed testing environment into a structured public health priority, thereby substantially increasing the annual volume of diagnostic assays. For example, according to the Ministry of Health and Family Welfare (India), in April 2025, the national screening initiative reported successfully screening 1,587,903 individuals for thalassemia as of March 2025, illustrating the immense scope of these government-led interventions.

Concurrently, technological progress in molecular diagnostics and the commercialization of gene therapies are redefining the market landscape by demanding precise genetic characterization. The authorization and deployment of gene-editing treatments necessitate stringent molecular testing to verify patient eligibility and track treatment success, consequently fueling the demand for high-complexity genetic tests. According to Vertex Pharmaceuticals' 'Second Quarter 2025 Financial Results' in August 2025, roughly 115 patients worldwide had commenced cell collection for the Casgevy gene therapy since its introduction, directly invigorating the market for companion diagnostic protocols. Nevertheless, inequalities persist; as noted by the Thalassaemia International Federation in March 2025, blood insufficiency remains a reality for more than 75% of patients in low- and middle-income countries, emphasizing the critical requirement for accessible diagnostic infrastructure to bolster both traditional and advanced therapeutic care.

Market Challenge

The major obstacle hindering the expansion of the Global Beta Thalassemia Testing Market is the acute lack of financial accessibility in resource-poor regions, stemming from inadequate healthcare funding and prohibitive out-of-pocket costs. In numerous emerging economies, the substantial expense linked to genetic verification creates a significant entry barrier. When families are compelled to shoulder the entire financial weight of healthcare, they often bypass preventative diagnostics to address immediate survival necessities, thereby dampening the demand for screening assays in areas with the highest genetic prevalence. This economic restriction effectively curtails the addressable market size, as diagnostic manufacturers find it difficult to enter territories where the healthcare infrastructure does not subsidize these vital tests.

Confirming this financial pressure, the Thalassaemia International Federation reported in 2024 that patients in over 90% of countries with medium to high disease prevalence remained reliant on out-of-pocket payments for their care. This strong dependence on personal funding is directly linked to reduced testing adoption rates, as the inability to pay for subsequent treatment makes the initial diagnosis financially unfeasible for a large portion of the at-risk population.

Market Trends

The rise of Point-of-Care (POC) diagnostic devices in decentralized environments is fundamentally transforming access to beta thalassemia testing, especially in areas devoid of centralized laboratory facilities. This trend marks a shift away from dependence on intricate High-Performance Liquid Chromatography (HPLC) systems toward portable, battery-powered units capable of providing definitive results in community clinics. These devices resolve critical logistical challenges by facilitating on-site screening and diagnosis, which drastically cuts patient drop-out rates caused by long travel distances for follow-up appointments. This evolution is drawing significant investment to expand manufacturing and distribution channels for these mobile solutions; for instance, MedAccess announced in September 2025 a strategic collaboration committing a $2.5 million working capital facility to Hemex Health to broaden access to its Gazelle diagnostic platform, the first portable device able to quantify hemoglobin variants for beta thalassemia in low-resource markets.

At the same time, the incorporation of Next-Generation Sequencing (NGS) for precision diagnosis is setting a new benchmark for detecting rare and complex mutations that conventional methods frequently overlook. As clinical management evolves toward personalization, laboratories are advancing beyond standard electrophoresis to high-throughput sequencing platforms capable of identifying non-deletional mutations and modifiers that influence disease severity. This technological shift is essential for averting severe birth defects through more exact carrier screening in diverse populations where genetic heterogeneity restricts the effectiveness of older screening instruments. Substantiating this enhanced precision, a study published in the 'Journal of Genetics and Genomics' by BGI Genomics in May 2025 revealed that applying high-throughput sequencing to 28,043 women of childbearing age facilitated the accurate identification of rare hemoglobin variants, proving a detection rate superior to that of traditional hematological screening methods.

Key Market Players

• MedGenome
• 3B BlackBio Biotech India Limited
• Bio-Rad Laboratories Inc.
• ViennaLab Diagnostics
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• BioMedomics Inc.
• Asper Biogene
• Tosoh Bioscience Inc

Report Scope

In this report, the Global Beta Thalassemia Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beta Thalassemia Testing Market, By Product

• Kits
• Consumables

Beta Thalassemia Testing Market, By Technology

• Prenatal Diagnosis
• Complete Blood Count
• DNA Testing
• Others

Beta Thalassemia Testing Market, By Type

• Thalassemia Major
• Thalassemia Intermedia

Beta Thalassemia Testing Market, By End-User

• Hospitals & Specialty Clinics
• Diagnostics Centers
• Others

Beta Thalassemia Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Beta Thalassemia Testing Market.

Available Customizations:

Global Beta Thalassemia Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Beta Thalassemia Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits, Consumables)
  • 5.2.2. By Technology (Prenatal Diagnosis, Complete Blood Count, DNA Testing, Others)
  • 5.2.3. By Type (Thalassemia Major, Thalassemia Intermedia)
  • 5.2.4. By End-User (Hospitals & Specialty Clinics, Diagnostics Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Beta Thalassemia Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Type
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Beta Thalassemia Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Type
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Beta Thalassemia Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Type
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Beta Thalassemia Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Type
      • 6.3.3.2.4. By End-User

7. Europe Beta Thalassemia Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Type
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Beta Thalassemia Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Type
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Beta Thalassemia Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Type
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Beta Thalassemia Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Type
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Beta Thalassemia Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Type
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Beta Thalassemia Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Type
      • 7.3.5.2.4. By End-User

8. Asia Pacific Beta Thalassemia Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Type
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Beta Thalassemia Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Type
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Beta Thalassemia Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Type
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Beta Thalassemia Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Type
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Beta Thalassemia Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Type
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Beta Thalassemia Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Type
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Beta Thalassemia Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Type
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Beta Thalassemia Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Type
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Beta Thalassemia Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Type
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Beta Thalassemia Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Type
      • 9.3.3.2.4. By End-User

10. South America Beta Thalassemia Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Type
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Beta Thalassemia Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Type
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Beta Thalassemia Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Type
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Beta Thalassemia Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Type
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Beta Thalassemia Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. MedGenome
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. 3B BlackBio Biotech India Limited
• 15.3. Bio-Rad Laboratories Inc.
• 15.4. ViennaLab Diagnostics
• 15.5. Thermo Fisher Scientific Inc.
• 15.6. PerkinElmer Inc.
• 15.7. BioMedomics Inc.
• 15.8. Asper Biogene
• 15.9. Tosoh Bioscience Inc

16. Strategic Recommendations

17. About Us & Disclaimer